Conclusions
Given the high cost-effectiveness of the ON101 with GWC strategy vs GWC alone for treating DFUs from the Taiwan health care sector perspective, the ON101-enhanced GWC may be considered in future standard wound care. Health care payers can consider the implementation of ON101 therapy to patients with an uninfected DFU with a Wagner grade of 1 or 2 and even prioritize it to those with poor glycemic control (HbA